![Rainer Kramer](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Rainer Kramer
Corporate Officer/Principal presso
IMMATICS N.V.
Patrimonio netto: - $ in data 31/08/2026
Profilo
Dr. Rainer Kramer is a Chief Business Officer at Immatics Biotechnologies GmbH and a Chief Business Officer at Immatics NV.
He is on the Board of Directors at iOmx Therapeutics AG and Immatics US, Inc. Dr. Kramer was previously employed as a Chief Business Officer by Signature Diagnostics AG, a Vice President-Business Development by Jerini AG, a Head-Business Development by MorphoSys AG, and a Principal by Amgen, Inc. He received his undergraduate degree from the University of Regensburg and a doctorate degree from Max Planck Institute of Neurobiology.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
IMMATICS N.V. -.--% | 18/03/2026 | 0 ( -.--% ) | - $ | 31/08/2026 |
Posizioni attive di Rainer Kramer
| Società | Posizione | Inizio |
|---|---|---|
| IMMATICS N.V. | Corporate Officer/Principal | 01/01/2012 |
Immatics Biotechnologies GmbH
 Immatics Biotechnologies GmbH BiotechnologyHealth Technology Operates as a bio technology company that develops and delivers T cell redirecting immunotherapies for treatment of cancer | Corporate Officer/Principal | 01/04/2012 |
Immatics US, Inc.
 Immatics US, Inc. BiotechnologyHealth Technology Develops adoptive cell therapies for treatment of cancer | Direttore/Membro del Consiglio | - |
iOmx Therapeutics AG
 iOmx Therapeutics AG BiotechnologyHealth Technology Develops immunotherapy treatments for cancer patients | Direttore/Membro del Consiglio | 20/07/2022 |
Precedenti posizioni note di Rainer Kramer
| Società | Posizione | Fine |
|---|---|---|
Signature Diagnostics AG
 Signature Diagnostics AG Pharmaceuticals: MajorHealth Technology Operates as a molecular diagnostics company | Corporate Officer/Principal | 01/05/2012 |
Shire Orphan Therapies GmbH
 Shire Orphan Therapies GmbH Pharmaceuticals: MajorHealth Technology Develops novel drugs | Corporate Officer/Principal | 01/08/2009 |
| MORPHOSYS AG | Corporate Officer/Principal | 01/01/2003 |
| AMGEN INC. | Corporate Officer/Principal | - |
Formazione di Rainer Kramer
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
68
Relazioni di 1° grado
10
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 10 |
|---|---|
Amgen, Inc.
 Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
MorphoSys AG
 MorphoSys AG BiotechnologyHealth Technology Manufactures pharmaceutical products and provides research and development services | Health Technology |
Shire Orphan Therapies GmbH
Shire Orphan Therapies GmbH Pharmaceuticals: MajorHealth Technology Develops novel drugs | Health Technology |
Immatics Biotechnologies GmbH
Immatics Biotechnologies GmbH BiotechnologyHealth Technology Operates as a bio technology company that develops and delivers T cell redirecting immunotherapies for treatment of cancer | Health Technology |
University of Regensburg
 University of Regensburg Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Signature Diagnostics AG
Signature Diagnostics AG Pharmaceuticals: MajorHealth Technology Operates as a molecular diagnostics company | Health Technology |
Max Planck Institute of Neurobiology
 Max Planck Institute of Neurobiology Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Immatics US, Inc.
Immatics US, Inc. BiotechnologyHealth Technology Develops adoptive cell therapies for treatment of cancer | Health Technology |
iOmx Therapeutics AG
iOmx Therapeutics AG BiotechnologyHealth Technology Develops immunotherapy treatments for cancer patients | Health Technology |
Immatics NV
 Immatics NV Pharmaceuticals: MajorHealth Technology Engages in developing immunotherapies for cancer treatments | Health Technology |
